August 23, 2021

How to cast a smarter net

Taking a new approach to expert identification can reshape outcomes for life science teams.
KOL selection

For many pharmaceutical and medical device teams, KOL selection can go one of two ways: defaulting to the list of KOLs they always use or outsourcing the work to a third party. Problem is, there are drawbacks to both approaches. Going back to the same people over and over again lets you talk to the experts you know best – but they might not be the best people to provide insight on every topic or therapeutic area. And hiring a third party can be time-consuming and expensive.

Related Posts:

Exploring the Within3 Insights Management Platform

A Look Under the Hood of Generative AI-Powered Insights
virtual clinical trials

What are virtual clinical trials?

A global pandemic disrupted countless clinical trials. What did pharma teams learn?